GRM8 and myeloid sarcoma: To then test whether specific activation of GRM8 is neuroprotective in the preclinical mouse model of MS, we subjected WT and Grm8−/− EAE to daily injections of 1 mg/kg body weight AZ i.p. starting on the day of disease onset.